Toward a modern search for schizophrenia genes by Leboyer, Marion.
Genetic epidemiology has provided consistent evidence
that schizophrenia has a genetic component. It is now
clear that this genetic component is complex and poly-
genic, with several genes interacting in epistasis.
Although molecular studies have failed to identify any
DNA variant that clearly contributes to vulnerability to
schizophrenia, several regions have been implicated by
linkage studies. To overcome the difficulties in the search
for schizophrenia genes, it is necessary (i) to use methods
of analysis that are appropriate for complex multifacto-
rial disorders; (ii) to gather large enough clinical sam-
ples; and (iii) in the absence of genetic validity of the
diagnostic classification currently used, to apply new
strategies in order to better define the affected pheno-
types. For this purpose, we describe here two strategies:
(i) the candidate symptom approach, which concerns
affected subjects and uses proband characteristics as the
affected phenotype, such as age at onset, severity, and
negative/positive symptoms; and (ii) the endophenotypic
approach, which concerns unaffected relatives and has
already provided positive findings with phenotypes, such
as P50 inhibitory gating or eye-movement dysfunctions.
century of research in genetic epidemiology
has consistently supported the involvement of a major,
complex, genetic component in the risk for schizophre-
nia. However, molecular genetic studies have produced
conflicting results: several chromosomal regions have
been implicated, but none of the findings met stringent
statistical significance criteria and positive findings have
not been replicated.This troublesome situation may be
partly attributed to obstacles that complicate efforts to
identify genes for any complex disorder, such as
unknown mode of inheritance, genetic heterogeneity,
phenocopies, incomplete penetrance, and variable
expressivity.
1 However,an even greater obstacle to iden-
tifying the genes underlying the vulnerability to schizo-
phrenic disorders is our inability to define the heritable
phenotype.
2 Indeed,although reliable diagnostic criteria
and structured psychiatric interviews have improved our
understanding of the genetics of schizophrenia, little is
known about how to choose the diagnostic system that
best describes the most heritable form of the illness or
the most heritable aspects of the psychopathology.Within
apparently affected subjects,various types of phenotypic
misclassifications reduce the power of linkage studies
because of phenocopies or genetic heterogeneity. Fur-
thermore, within apparently unaffected subjects or con-
trols, our inability to identify nonaffected subjects car-
rying vulnerable genes, due to incomplete penetrance,
also reduces the power of association studies.
Despite this apparently confusing situation, two major
conclusions can be drawn from the research published so
far.First,the pattern of risk in families suggests that sev-
eral genes in epistasis lead to schizophrenia
3;thus,instead
of searching for the schizophrenia gene, genetic studies
should now be designed to search for many genes with
small effects.Second,in order to minimize the arbitrari-
ness of categorical diagnoses,new strategies must be used
to define phenotypes as subclinical quantitative traits,ie,
endophenotypes.
2 Quantitative measures that are more
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Pharmacological aspectsclosely related to schizophrenia genes provide more
power in linkage analyses than categorical diagnoses and
might be valuable for identifying common alleles with
nonspecific and moderate effects on disease risk.
4 Fur-
thermore, an endophenotype might be underlined by a
mendelian inheritance pattern, which would consider-
ably diminish the sample size required to detect the
responsible genetic mutation.
5 This alternative pheno-
typic strategy has already yielded positive results: schiz-
ophrenia linkage studies using two endophenotypes,eye-
tracking
6 and P50 evoked potential measurements,
7 as
phenotypes have suggested genetic linkage in popula-
tions where the clinical diagnosis did not.
This review will first describe the classic genetic argu-
ments in favor of the existence of a genetic component
in schizophrenia and the results obtained by linkage and
association studies.It will then discuss the existing liter-
ature on potential candidate symptoms or characteristics
in schizophrenic probands and endophenotypes in their
unaffected relatives, including the clinical, cognitive,
electrophysiological, and biochemical characteristics
examined in studies.
Why are we looking for genes 
contributing to schizophrenia?
Data collected from families, twins, and adoptees have
consistently supported the involvement of genetic fac-
tors in schizophrenia.The combined results from Euro-
pean studies
8 yield a lifetime morbid risk in the general
population of 1%, while the risk for schizophrenia in
siblings or offspring of a schizophrenic proband is close
to 10%.This risk varies according to the type of schizo-
phrenia:the risk of becoming schizophrenic for a child of
a hebephrenic or catatonic schizophrenic parent is
20.7% and 21.6%, respectively. This risk is decreased
(10.4%) for a child of a paranoid schizophrenic parent.
Risk is also increased when more relatives are affected,
for example,the morbid risk of schizophrenia for a child
of two affected parents is 46%.The risk for other con-
ditions is increased among relatives of schizophrenic
patients. In particular, Kendler and Diehl
9 have shown
that the risk of schizotypal or paranoid personality dis-
orders in relatives of schizotypal patients is four times
that in control families.The risks of schizoaffective dis-
order, schizophreniform disorder, delusional disorders,
and atypical psychosis are also significantly increased in
the relatives of probands.
Altogether,these data clearly demonstrate the existence
of a family concentration of schizophrenia.Twin studies
provide an estimation of the importance of the genetic
contribution.They have shown consistent evidence of a
higher concordance for monozygotic (50%) than dizy-
gotic (17%) twins
10 and estimated the heritability for
schizophrenia as close to 80%.
11 Gottesman and Ber-
telsen
12 showed that rates of schizophrenia in offspring
of identical twins discordant for schizophrenia were
equal. These data suggest that individuals who possess
the schizophrenia genotype do not necessarily express
the disorder.
Studies of twins clearly show that liability to schizo-
phrenia is not completely genetic and is more likely a
complex trait determined by several genes interacting
with the environment. Better knowledge of environ-
mental risk factors may improve our ability to identify
the genes for schizophrenia.In particular,there is now a
reliable evidence that at least two environmental fac-
tors are involved in the etiology of schizophrenia: peri-
natal obstetric complications
13 and prenatal viral infec-
tions, especially in the second trimester.
14 No study has
clearly answered the question of how the genetic risk
interacts with environmental precipitants or is transmit-
ted. However, the most consistent model of transmis-
sion is a multifactorial inheritance model with no major
gene.
15 Risch et al
3 have also shown that data in schizo-
phrenia are consistent with the existence of three to four
loci interacting epistatically. It is very likely that when
the number of loci increases,the risk alleles at these loci
become very common in the population,of the order of
14% to 20%.
16
Which chromosomal regions are 
the best candidates for containing 
schizophrenia susceptibility genes?
Molecular genetic studies have so far failed to find any
DNA variant that can be demonstrated to contribute to
schizophrenia risk. Replication of positive findings has
been difficult to interpret and, when positive replica-
tions have been obtained, the positioning of the locus
has been unreliable, leading no closer to positional
cloning of the putative gene. In addition, many regions
are implicated, and the lod scores obtained are always
below the threshold suggested by Morton for mendelian
traits.
17 However, review of all the linkage studies per-
formed over the past 10 years does suggest a number
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of regions where small positive lod scores have been
found several times in independent samples (for a recent
review,see reference 18).
• Chromosome 1. Positive linkage findings have been
found in the region 1q42.1,
19 where the breakpoint of
a balanced 1:11 translocation segregating with schiz-
ophrenia in a large schizophrenia pedigree from Scot-
land was found.
20
• Chromosome 2. Interest in the region 2p22-q21 came
from a case report of a balanced 2:18 translocation
segregating in a family with schizophrenia.
21 Since
then,there have been several reports of positive link-
age with markers spread over 100 cM of the region
2p22-q21.
22
• Chromosome 3. Initial positive results in the region 3p
24
were obtained by Pulver et al,
23 but were not replicated
later by the Schizophrenia Linkage Collaborative
Group Study. The only further data implicating this
region come from the report of an excess homozygosity
for one allele of a polymorphism in the dopamine
receptor D3 gene.
24 Steen et al
25 reported an associa-
tion of DRD3 allele and tardive dyskinesia in schizo-
phrenic patients and Krebs et al
26 reported an associa-
tion of homozygosity with substance abuse in
schizophrenic patients.
• Chromosome 4.Conflicting results were obtained fol-
lowing the initial report of a linkage with a cluster of
three markers on the region 4q24-q32.
27This region is
interesting as positive reports have also been obtained
here for bipolar disorders.
28
• Chromosome 5.After nonreplication of the first posi-
tive linkage result obtained in schizophrenia,
29 there
was renewed interest in chromosome 5 when two sep-
arate series of positive linkages were obtained in
regions 5p14.1
30 and 5q22-q31.
31
• Chromosome 6. Several independent positive reports
of the region 6p24-p22 have been published,
32 and it is
noteworthy that eye-tracking dysfunction, a widely
used endophenotype, has been mapped to the p arm
of chromosome 6. Positive linkage findings were
reported in the region 6q21-q22.3,but these have not
yet been replicated by an independent group.
33
• Chromosome 7.Two studies obtained moderately pos-
itive results in the region 7q21.1-q21.3 using three
markers spread over 30 cM of the chromosome.
34
• Chromosome 8. Four independent studies have
reported positive results in the region 8p22-p21 fol-
lowing an initial report of Pulver et al.
23
• Chromosome 9. Several positive results have been
published for linkage to the region 9q34.3, which
contains several candidate genes, such as those
dopamine-β -hydroxylase (DBH) and the critical
subunit of the N-methyl-D-aspartate (NMDA)
receptor NR1. So far, negative linkage results have
been obtained with the DBH gene.
35
• Chromosome 13. The region 13q codes for the sero-
tonin receptor 5-HT2A gene, which has been
reported to be associated with schizophrenia.
36 Pos-
itive lod scores have been obtained with indepen-
dent samples from Europe, Asia, Africa, USA, or
Canada.
• Chromosome 15. The first evidence for a possible
implication of chromosome 15 was the report of
linkage with P50 sensory gating deficit in the
region 15q13-q14.
37 A positive lod score was
obtained with the gene encoding the  7 nicotinic
cholinergic receptor subunit (CHRNA7) when
using the sensory gating phenotype; the lod score
dropped when using schizophrenia as the pheno-
type. With polymorphic markers located in the
same regions, positive results have been obtained
by several groups, while two studies failed to find
any evidence for involvement of this region.
38,39
• Chromosome 18. Interest in chromosome 18 began
with the report of positive linkage with bipolar dis-
order.
40 Positive results, not always replicated, have
mostly been obtained when including both affective
disorders and schizophrenia as the affected pheno-
type.
41 Positive results have been obtained with the
gene encoding for the subunit of the olfactory G-
protein (GOLF).
• Chromosome 22. Discrepant results have been
obtained with markers spanning chromosome 22,
which is also known to be associated with velocar-
diofacial syndrome (VCFS). Thirty percent of
patients presenting with this syndrome carry a diag-
nosis of schizophrenia.
42The gene encoding for cate-
chol-O-methyl transferase (COMT) is located in the
region 22q11 and has been suggested to be involved
with the psychotic symptoms observed in VCFS.
43
• X chromosome. The X chromosome was initially sug-
gested to be a chromosome of interest due to the
well-known gender differences in schizophrenia.A
pseudoautosomal locus that would account for those
differences was suggested by Crow et al.
44 Dis-
crepant results were obtained thereafter.
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Results have already been published in the field of schiz-
ophrenia pharmacogenetics.In particular,an association
has been reported between the D4 receptor gene and
good response to clozapine,
45 while nonresponders to
clozapine demonstrated associations with particular alle-
les of the 5-HT2A receptor gene.
46 These findings have
not always been replicated,dampening enthusiasm.
Altogether, all these results may appear confusing.The
clinical heterogeneity of the illness is one of several
explanations for these discrepancies.The use of linkage
analysis methods in comparison with nonparametric
methods (which do not apply any assumptions on the
mode of inheritance) has been thoroughly discussed.
The value of performing association studies testing the
implication of candidate genes is clear. However, Riley
and McGuffin
18 have emphasized that larger clinical
samples than originally anticipated will be needed both
for studies in multiply affected families and for sporadic
cases.Also,because the power of molecular genetic stud-
ies derives not only from sample size, but also from the
accuracy of the phenotypic definition, we and others
have advocated the need for the development of more
powerful phenotypic strategies.
2,4
What is the best strategy 
to improve phenotype identification? 
The genetic validity of the current customary criteria
for standardized diagnosis has not been demonstrated.
We have suggested two complementary strategies for
finding genetically valid traits:one involves a description
of the affected subjects;and the other involves the iden-
tification of vulnerability traits in nonaffected relatives
of affected individuals,ie,the endophenotypic approach.
The first strategy utilizes affected individuals and is
called the candidate symptom approach. It is analogous to
the candidate gene approach as applied in molecular
biology.The candidate symptom approach would iden-
tify several stringent clinical characteristics hypotheti-
cally associated with a disease genotype and show a pat-
tern of inheritance related more robustly to the narrow
characteristics than to the diagnosis. Identification of
specific subforms of the disorder would lead to identifi-
cation of homogeneous families,which are more appro-
priate for linkage studies.
The second strategy emphasizes the need to use broader
approaches, such as related biochemical, neurophysio-
logical, neuroanatomical, cognitive, and/or neuropsy-
chological markers, to identify pertinent phenotypes in
nonaffected relatives carrying vulnerability genes.These
subclinical associated traits, endophenotypes, might be
valuable for identifying common alleles with nonspe-
cific and moderate effects on disease risk. Thus,
endophenotypes serve to better define the trait or its
underlying genetic mechanism.
47 To meet criteria for a
marker trait,an endophenotype should be measured in
an objective and cost-effective fashion among clinically
unaffected relatives of patients,should occur before the
onset of illness, should run in families, and should be
associated with increased risk of clinical illness. This
strategy is recommended for psychiatric disorders in
which symptoms occur as the consequence of an inter-
action between several vulnerability factors,each having
good genetic validity but not necessarily disease-speci-
ficity.
The candidate symptom strategy
Target symptoms that could allow the identification of a
homogeneous form of the illness (ie, candidate symp-
toms) should fulfill the following criteria: they should
show good concordance rates among affected monozy-
gotic twins and should be correlated in pairs of affected
siblings.
48This strategy has already proven helpful in the
identification of subgroups in complex disorders other
than psychiatric disorders. For example, subdivision
according to age at onset has been particularly efficient
in clarifying genetic heterogeneity in dementias of the
Alzheimer’s type. The amyloid precursor protein was
initially falsely excluded as a susceptibility locus under
the incorrect assumption that all cases of familial
Alzheimer’s disease were caused by the same gene.
49
Later,direct sequence analysis of the amyloid precursor
protein gene revealed mutations at this locus on the q
arm of chromosome 21 segregating with the disease in
pedigrees of Alzheimer’s disease cases with onset by age
60.
50 Later, other loci were found to be involved. Most
early-onset autosomal dominant forms of Alzheimer’s
disease have been linked to a defective gene on the q
arm of chromosome 14,whereas the late-onset sporadic
forms of Alzheimer’s disease are associated with the
apolipoprotein E4 allele on chromosome 19.
Similarly,in the field of schizophrenia,age at onset may
be a good candidate symptom: early onset is associated
with increased familial risk in schizophrenia.
51 Further-
more, age at onset in schizophrenia appears to be sub-
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stantially influenced by familial factors, since correla-
tion with age at onset in affected pairs of siblings ranges
from 0.2 to 0.4,
52,53 and that of monozygotic twins ranges
from 0.5 to 0.8.
52 Of interest is that schizophrenic females
with late onset and no family history of schizophrenia
seem to form a subgroup of patients with a hormonal
basis for their illness.
54,55 Furthermore, the decrease in
age at onset of schizophrenia in successive generations
seems to be consistent with the phenomenon of genetic
anticipation.
56
The occurrence of specific symptom constellations may
also help in identifying a subgroup of genetically related
schizophrenia subtypes, which are etiologically homo-
geneous.Anhedonia, blunted affect, poverty of speech,
lack of a sense of purpose, and diminished social drive
can be considered as enduring symptoms that are core
manifestations of schizophrenia.
57 Indeed, negative
symptoms are more stable over time than positive symp-
toms
58 and seem to be the main source of familial aggre-
gation in schizophrenia. A twin study by Dworkin and
Lenzenweger
59 found an increased concordance rate for
schizophrenic twins with two or more negative symp-
toms, but not for positive symptoms. They also found
that negative symptoms,but not positive symptoms,were
correlated between pairs concordant for schizophrenia.
Sautter et al
60 found that a family history of schizophre-
nia correlated with negative symptoms. Kay et al
61
reported that negative symptoms were positively corre-
lated with a family history of major psychiatric disor-
ders, but negatively correlated with a family history of
affective disorders.Tsuang
4 showed that negative symp-
tom ratings are higher for relatives of patients with
schizophrenia, whereas positive symptom ratings are
similar in relatives of schizophrenic patients and
depressed controls.These findings suggest that negative
symptoms could reflect familial liability to schizophre-
nia, whereas positive symptoms reflect a clinical
endophenotype common to both affective disorders and
schizophrenia. Indeed, several studies have demon-
strated familial relationships between schizophrenia and
affective disorders,in particular with psychotic affective
disorders.
62Thus,one might hypothesize that the shared
candidate symptom might be represented by positive
symptoms.Brzustowicz et al
63 provided the first evidence
of the value of using a quantitative dimensional
approach in a linkage study in a sample of multiply
affected families.Positive linkage with markers on the p
arm of chromosome 6 was obtained only when using
scores on positive symptoms as phenotypes among schiz-
ophrenic patients and their nonaffected relatives.Nega-
tive linkage results were obtained with negative scores
or with a classical nosographical approach.
The endophenotype strategy
Endophenotypes are traits that are associated with the
expression of an illness and are believed to represent
the genetic liability of the disorder among nonaffected
subjects. Using the endophenotypic strategy, schizo-
phrenia can be conceptualized as an illness caused by
the interaction of several elementary neurobiological
dysfunctions—each underlined by a specific defect in a
particular candidate gene—with nongenetic factors.
There are several examples of somatic diseases in which
“endophenotypic” level helped define the genetic basis
of the illness in molecular terms. For instance, under-
standing the mode of inheritance of idiopathic hemo-
chromatosis was unclear until serum iron concentration
was selected as a biological indicator of intrinsic liability
to the disease. Including serum iron in the analysis
uncovered a linkage with the HLA-A locus.
64 In order to
identify a genetic susceptibility factor in juvenile
myoclonic epilepsy,investigators chose a subclinical trait
(ie,an abnormal electroencephalogram) as an endophe-
notype in affected and nonaffected family members,and
found linkage to chromosome 6.
65 Focusing on families
with the highest serum glucose levels as a specific phe-
notype led to the discovery of a genetic deficit that
results in type 2 diabetes.
66
In schizophrenia, several neurochemical, electrophysi-
ological,and cognitive abnormalities have been reported
among nonaffected relatives of schizophrenic patients.
Two endophenotypes in particular, eye tracking
6 and
P50 evoked potential measurements,
7 have already been
used as phenotypes,and yielded positive linkage results.
Neurochemical abnormalities
Investigations of neurochemical abnormalities among
unaffected relatives of schizophrenic patients is a con-
venient method to explore biochemical predisposition to
schizophrenia in natural conditions, without any phar-
macological challenge and in the absence of confound-
ing factors,such as chronicity of illness or effects of med-
ication.Dopaminergic abnormalities have been explored
in nonpsychotic relatives under the hypothesis that neg-ative and positive symptoms are associated with
decreased and increased brain dopamine (DA) func-
tions,respectively.Decreased plasma homovanillic acid
(HVA), the major DA metabolite, has been observed
in healthy first-degree relatives of schizophrenic
probands.
67 Few studies of the proteins involved in DA
uptake and metabolism have been performed in unaf-
fected relatives of schizophrenic patients. However,
increased densities of DA receptors ([
3H]spiperone
binding sites) on lymphocytes has been reported in one
third of the well relatives of schizophrenic probands.
68
Regarding serotonergic parameters, two studies have
reported higher cerebrospinal fluid 5-hydroxyindolea-
cetic acid (5-HIAA) concentrations in schizophrenia
patients with a strong positive family history of schizo-
phrenia.
69,70To our knowledge,studies of neuroendocrine
measures and platelet markers of 5-HT function have
not yet been undertaken in individuals at risk for schiz-
ophrenia.
Electrophysiological markers
Cognitive event-related potentials (ERPs) have been
widely used as potential indicators of risk for schizo-
phrenia. ERPs are usually measured in terms of ampli-
tude, latency, and topography of a component. ERPs
elicited by infrequent auditory targets,for example,dur-
ing an oddball paradigm,are characterized successively
by (i) an early component,N100,which reflects the sen-
sory analysis of the physical parameters of the stimu-
lus
71; (ii) N200, which evaluates selective attention
processes leading to stimulus categorization
72; and (iii)
P300, which is classically related to the postperceptual
updating of short-term working memory traces of
expected environmental stimuli.The ERP technique is a
safe,noninvasive approach to the study of psychophys-
iological correlates of human mental processes.
The most robust finding is that of reduced P300 ampli-
tude and increased amplitude using an oddball para-
digm in schizophrenic patients compared with controls.
This finding can be considered as a trait marker,since it
has been reported in unmedicated schizophrenic
patients using an auditory modality, whereas the visual
modality may serve as state marker.
73-75 Altogether, the
delayed P300 in schizophrenic patients appears to be
independent of a medication effect, the clinical state,
76
the duration of symptoms, and the clinical subtype of
the illness.
75 However, reduced P300 is not specific to
schizophrenia,since it has been reported in a variety of
different disorders, such as dementia, alcoholism, and
bipolar disorder.
Several high-risk studies have provided evidence that
P300 abnormalities can be considered as a vulnerability
indicator. For example, Blackwood et al
77 found P300
amplitude reduction and latency prolongation in a sam-
ple of patients with schizophrenia,and half of their non-
schizophrenic relatives showed prolonged P300 latency.
However, these results have not always be replicated.
Other abnormalities of the components of the ERPs
have been observed in schizophrenia. Schizophrenic
patients and their relatives showed similar amplitude
reduction and latency prolongation of the N100,N200,
and P300 waves compared with controls.
78 However,
N100 reduction is not specific to schizophrenia since it
is also observed in patients with major depressive dis-
order. The N100 reduction might be the result of an
overlapping component, the processing negativity,
which is elicited during selective attention paradigms
and appears to be reduced in schizophrenia patients.
A reduction in processing negativity is consistent with
the deficits in selective attention that have been pro-
posed to account for some schizophrenic symptoma-
tology.
To date,the only endophenotype whose linkage analy-
sis has pointed to a specific candidate mechanism for
neuronal dysfunction in schizophrenia comes from the
work on the sensory gating dysfunction by the group
led by Freedman.
5The paradigm used was to present to
the subject pairs of identical stimuli. Normal subjects
diminish the amplitudes of the P50 wave response to
the second stimulus, whereas schizophrenic patients
consistently have a deficit in P50 inhibition.
79 This
deficit is present in the unaffected parents of schizo-
phrenic probands, who have themselves an ancestral
family history of schizophrenia, but not in parents
without such histories.
80 Furthermore, the families of
early-onset schizophrenia show bilineal inheritance of
the P50 inhibitory deficit, ie, both parents are
affected.
81 Thus, bilineal inheritance may be related to
more severe and earlier illness onset. Animal studies
showed that the inhibition of the second stimulus is
mediated through cholinergic activation of hippocam-
pal interneurons mediated via α 7 nicotinic receptors.In
schizophrenics and their relatives, nicotine transiently
normalizes the deficit in P50 inhibition,
82 as predicted
from the animal model.The gene encoding the α 7 nico-
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tinic receptor is localized in the region 15q14,a region
of chromosome 15 found to be linked to schizophrenia
in several genome scans.Freedman et al
37 showed that
the P50 defect maps to the site of the α 7 nicotinic
receptor gene with a lod score of 5.3 under an autoso-
mal dominant model. Replication of these data, iden-
tification of the molecular abnormality, and determi-
nation of the role of the abnormality in the
pathogenesis of schizophrenia are necessary as the
next steps.
Eye movement
Hundreds of studies have described the characteristic
eye-movement dysfunction (EMD) in schizophrenic
patients (for a review, see reference 83). This smooth
pursuit dysfunction is stable over time,
84 present during
symptom remission,
85 and familial,as it is found in almost
50% of unaffected relatives.
85 Schizophrenic patients and
their relatives also demonstrate a deficiency in their abil-
ity to inhibit reflex saccades to the target.
86Antisaccades
EMD is found only in relatives of schizophrenic patients
who themselves have increased rates of errors. These
data suggest that abnormal smooth pursuit and saccade
dysfunction are familial.
87 Although both types of abnor-
malities have been related to impaired frontal cortex
functioning, especially in the A9 region, it is not yet
known if these two dysfunctions are related to a distinct
genetic risk or a single neural factor. In particular, no
study has simultaneously investigated the relationship
between smooth pursuit and saccadic system among
schizophrenic patients. Only one study used abnormal
smooth pursuit as an endophenotype in a linkage study
reporting linkage of pursuit EMD to chromosome 6.
6
However,these results need to be replicated.
Cognitive markers
Numerous studies suggest that relatives of schizophrenic
patients exhibit neuropsychological impairments that
are milder than, and yet similar to, those observed in
schizophrenic patients. In particular, the relatives of
schizophrenic patients have been demonstrated to show
disturbances of executive functioning, verbal memory,
auditory attention, mental control, and verbal ability.
88
These abnormalities are stable over time
89 and are
observed in nonschizophrenic family members of
patients; moreover, nonschizophrenic, monozygotic
cotwins produce more persevering responses in the Wis-
consin Card Sorting Test than controls.
90,91 
Another relevant strategy to identify endophenotypes is
to perform high-risk studies on offspring of schizophrenic
patients. Offspring were shown to have attention diffi-
culties, poor performance on memory tasks, poor global
adjustment, poor social competence, and anhedonia.
92
Abnormalities in verbal short-term memory, related to
amplitude decrements in the P300 component of ERP,
and attention digit-span tasks predicted 83% of the off-
spring who developed adulthood schizophrenia.
93 Before
demonstrating that a neurocognitive abnormality is an
endophenotype,many variables must be tested for replic-
ability over studies,stability over time,and heritability.
Conclusions
Altogether, research into the genetic basis of schizo-
phrenia is productive but complex,and can be frustrat-
ing.Nevertheless,the field is slowly moving toward new
methods of analysis,by searching alternative phenotypic
definition and making collaborative efforts to gather
samples large enough for analysis.❑
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Hacia una investigación moderna de los
genes de la esquizofrenia
La epidemiología genética ha aportado evi-
dencias consistentes acerca del componente
genético que tiene la esquizofrenia. Hoy en día
está claro que este componente genético es
complejo y poligénico, con algunos genes que
actúan en la epistasis. Aunque los estudios
moleculares han fracasado en la identificación
de alguna variante del ADN que claramente
contribuya a la vulnerabilidad para la esquizo-
frenia, mediante estudios de enlace se han
propuesto varias regiones que pudieran estar
involucradas. Para superar las dificultades en la
investigación de la esquizofrenia es necesario:
1) emplear métodos de análisis que sean apro-
piados para los trastornos multifactoriales com-
plejos, 2) reunir muestras clínicas bastante
grandes y 3) en ausencia de una validez gené-
tica de la clasificación diagnóstica actualmente
en uso, aplicar estrategias de manera de defi-
nir mejor los fenotipos afectados. Para este
propósito, nosotros describimos aquí dos estra-
tegias: 1) la aproximación del síntoma candida-
to, que incluye a los sujetos afectados y se vale
de las características del probando en cuanto al
fenotipo afectado como son la edad de
comienzo, la severidad y los síntomas negativos
/ positivos y 2) la aproximación endofenotípica,
que incluye a los familiares no afectados y que
ya tienen hallazgos positivos con los fenotipos,
como la onda P50 inhibitoria o disfunciones de
la motilidad ocular.
Vers une modernisation de la recherche sur
les gènes de la schizophrénie
L’épidémiologie génétique a fourni des résultats
concordants prouvant que la schizophrénie a une
composante génétique. Il est maintenant clair
que cette composante génétique est complexe
et polygénique avec plusieurs gènes interagis-
sant en épistasie. Bien que les études molécu-
laires n’aient pas réussi à identifier un quel-
conque variant d’ADN qui contribue de façon
certaine à la vulnérabilité à la schizophrénie, plu-
sieurs régions ont été impliquées par les études
de liaison. Pour surmonter les difficultés de la
recherche des gènes intervenant dans la schizo-
phrénie, il est nécessaire : (1) d’utiliser des
méthodes d’analyse qui sont adaptées aux
troubles multifactoriels complexes ; (2) de réunir
des échantillons cliniques suffisamment larges ;
et (3) en l’absence de validation génétique de la
classification diagnostique habituellement utili-
sée, d’appliquer de nouvelles stratégies afin de
mieux définir les phénotypes impliqués. Pour
atteindre cet objectif nous exposons ici deux stra-
tégies : (1) l’approche du symptôme candidat,
qui concerne les patients atteints de la maladie
et qui utilise les caractéristiques des patients
comme phénotype affecté tels l’âge de surve-
nue, la sévérité de la maladie et les symptômes
négatifs et positifs; et (2) l’approche endophé-
notypique, qui concerne les proches parents non
atteints et qui a déjà fourni des résultats positifs
avec les phénotypes, tels que le niveau d’inhibi-
tion P50 ou les dysfonctionnements des mouve-
ments oculaires.Toward a modern search for schizophrenia genes - Leboyer Dialogues in Clinical Neuroscience - Vol 3 . No.2 . 2001
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